It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Novel bacterial type II topoisomerase inhibitors (NBTIs) stabilize single-strand DNA cleavage breaks by DNA gyrase but their exact mechanism of action has remained hypothetical until now. We have designed a small library of NBTIs with an improved DNA gyrase-binding moiety resulting in low nanomolar inhibition and very potent antibacterial activity. They stabilize single-stranded cleavage complexes and, importantly, we have obtained the crystal structure where an NBTI binds gyrase–DNA in a single conformation lacking apparent static disorder. This directly proves the previously postulated NBTI mechanism of action and shows that they stabilize single-strand cleavage through asymmetric intercalation with a shift of the scissile phosphate. This crystal stucture shows that the chlorine forms a halogen bond with the backbone carbonyls of the two symmetry-related Ala68 residues. To the best of our knowledge, such a so-called symmetrical bifurcated halogen bond has not been identified in a biological system until now.
The mechanism of DNA gyrase inhibitor stabilization of single-strand DNA cleavage breaks by DNA gyrase has been hypothetical. Here, the authors show experimental evidence of the mechanism using a library of inhibitors with improved binding and employ crystal analysis to show bifurcated halogen bonding.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 National Institute of Chemistry, Theory Department, Laboratory for Cheminformatics, Ljubljana, Slovenia (GRID:grid.454324.0) (ISNI:0000 0001 0661 0844); University of Ljubljana, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ljubljana, Slovenia (GRID:grid.8954.0) (ISNI:0000 0001 0721 6013)
2 John Innes Centre, Department of Biological Chemistry, Norwich, UK (GRID:grid.14830.3e) (ISNI:0000 0001 2175 7246)
3 University of Ljubljana, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ljubljana, Slovenia (GRID:grid.8954.0) (ISNI:0000 0001 0721 6013)
4 Inspiralis Ltd., Innovation Centre, Norwich, UK (GRID:grid.14830.3e)
5 National Institute of Chemistry, Theory Department, Laboratory for Cheminformatics, Ljubljana, Slovenia (GRID:grid.454324.0) (ISNI:0000 0001 0661 0844)